Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
Morgagni-Pierantoni Hospital, Forlì, Italy.
Br J Cancer. 2023 May;128(9):1665-1671. doi: 10.1038/s41416-023-02188-z. Epub 2023 Feb 17.
Treatment of hepatocellular carcinoma (HCC) is predicated on early diagnosis such that 'curative therapies' can be successfully applied. The term 'curative' is, however, poorly quantitated. We aimed to complement our previous work by developing a statistical model to predict cure after ablation and to use this analysis to compare the true curative potential of the various 'curative' therapies.
We accessed data from 1571 HCC patients treated in 5 centres receiving radiofrequency (RFA) or microwave (MWA) ablation and used flexible parametric modelling to determine the curative fraction. The results of this analysis were then combined with our previous estimations to provide a simple calculator applicable to all patients undergoing potentially curative therapies.
The cure fraction was 18.3% rising to about 40% in patients with good liver function and very small tumours.
Cure for HCC treated with ablation occurs in the order of 20% to 30%, similar to that achievable by resection but much inferior to transplantation where the analogous figure is >70%. We provide a 'calculator' that permits clinicians to estimate the chance of cure for any individual patient, based on readily available clinical features.
肝细胞癌 (HCC) 的治疗取决于早期诊断,以便能够成功应用“治愈性疗法”。然而,“治愈性”这个术语并没有被很好地量化。我们旨在通过开发一个统计模型来预测消融后的治愈情况,并利用这种分析来比较各种“治愈性”疗法的真正治愈潜力,从而补充我们之前的工作。
我们从 5 个中心接受射频 (RFA) 或微波 (MWA) 消融治疗的 1571 名 HCC 患者的数据中进行了评估,并使用灵活的参数建模来确定治愈分数。然后,我们将分析结果与我们之前的估计相结合,为所有接受潜在治愈性治疗的患者提供了一个简单的计算器。
治愈分数为 18.3%,在肝功能良好且肿瘤非常小的患者中上升至约 40%。
消融治疗的 HCC 治愈发生在 20%至 30%左右,与切除术相当,但远低于移植术,后者的类似比例超过 70%。我们提供了一个“计算器”,允许临床医生根据易于获得的临床特征来估计任何个体患者的治愈机会。